Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
TIGIT
Biotech
Gilead loosens ties to Arcus as TIGIT dream ends in ph. 3 fail
Gilead and Arcus’ domvanalimab has failed another trial—leading Gilead to pull further away from their once wide-ranging collaboration.
James Waldron
Apr 21, 2026 3:07am
Arcus halts Gilead-partnered TIGIT trials as it reworks R&D
Dec 12, 2025 10:00am
GSK loses hope for CD226 cancer therapies, dropping ph. 2 assets
Oct 29, 2025 6:29am
Gilead, Arcus keep TIGIT dream alive with 27-month OS data
Oct 13, 2025 7:05am
GSK anti-TIM-3 antibody flunks ph. 3, as TIGIT fail costs $629M
Jul 30, 2025 5:27am
iTeos, reeling from TIGIT fail, is latest prize for Concentra
Jul 21, 2025 9:36am
